Assessment of a Cosmetic Product Effect on the Host/Microorganism Relationship in Acneic Subjects
Launched by PIERRE FABRE DERMO COSMETIQUE · Nov 28, 2022
Trial Information
Current as of February 05, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- 1. Related to the population:
- • - Subject aged between 12 to 25 years included
- 2. Related to diseases:
- • Subject having acne lesions on the face, with GEA (Global Acne Evaluation) score on the face is assessed as 2 (mild) or as 3 (moderate), on a scale ranged from 0 (clear- no lesion) to 5 (very severe)
- • Subject having at least 20 open-comedones of about 1 mm in diameter on the face and possibly extractable
- • Subject having a predominance of non-inflammatory acne lesions
- Exclusion Criteria:
- 1. Related to diseases:
- • Subject having comedones only on the nose wings
- • Subject with any other dermatological disease than acne or skin characteristics (like scar, tatoo) on the face liable to interfere with the study according to the investigator's assessment
- • Subject with an acute or chronic disease, or history of disease liable to interfere with the study data or considered by the Investigator hazardous for the subject or incompatible with the study requirements
- • Severe form of acne (Acne conglobata, Acne fulminans or nodulokystic acne) or acneiform induced rashes according to the investigator's assessment
- • Clinical signs of a hormonal dysfunction or of a hyperandrogenism
- • Solar erythema on the face due to excessive UV exposur
- 2. Related to the treatments/products:
- • Any previous/concomitant treatment or product considered by the Investigator liable to interfere with the study data or incompatible with the study requirements or hazardous for the subject
Trial Officials
Pascal REYGAGNE
Principal Investigator
Centre de Santé Sabouraud
About Pierre Fabre Dermo Cosmetique
Pierre Fabre Dermo-Cosmétique is a leading global player in the dermatology and dermo-cosmetics sectors, dedicated to developing innovative products that address a wide range of skin conditions and enhance skin health. Established as a subsidiary of Pierre Fabre Group, the company combines scientific expertise with a commitment to quality and efficacy, ensuring that its offerings are grounded in rigorous research and clinical validation. With a strong portfolio of brands, Pierre Fabre Dermo-Cosmétique focuses on patient-centric solutions, aiming to improve the quality of life for individuals with sensitive or compromised skin. The company's strategic approach to clinical trials underscores its dedication to advancing dermatological science and delivering reliable, safe products to healthcare professionals and consumers alike.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Toulouse, , France
Paris, , France
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials